Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.
It is the largest venture capital fund in Europe focused on the life sciences.
Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.
The vote to offer a booster to those 65 and older, as well as immunocompromised individuals at high risk of developing severe COVID-19, was a unanimous “yea” at 18-0.
One constant throughout the conversation is that the industry is at a different stage of adapting to the “new normal.”
From time to time, the U.S. FDA requests additional data from companies who have submitted an application for a new drug or biologic. What’s a bit unusual is every single PDUFA date this week had that happen.
In a late-breaking presentation on Saturday, EQRx and partner CStone Pharmaceuticals will report data from the phase III GEMSTONE-301 study of its anti-PD-L1 antibody sugemalimab.
COVID-19 remains relentless in challenging the community as it continues to evolve. Here are some of the top news for the week.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
Gilead announced its plans to replant some roots back in North Carolina’s Research Triangle. The new site is expected to bring in 275 jobs to the North Hills innovation district.
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
Vifor Pharma Group and Travere Therapeutics inked a collaborationfor the commercialization of sparsentan for the treatment rare progressive kidney diseases.